Gimlette T M
Department of Nuclear Medicine, Royal Liverpool Hospital, Liverpool, England.
Nuklearmedizin. 1989 Feb;28(1):21-5.
99mTc-pertechnetate uptake was estimated 8-13 weeks after radioiodine therapy for hyperthyroidism in 132 patients in order to evaluate the usefulness of the uptake test in predicting both persisting hyperthyroidism and the early onset of hypothyroidism during the first year after therapy. The estimation was simple, the result immediately available, and its sensitivities, positive predictive value and its overall accuracy (83%) compared favourably with that of in-vitro tests, FT4I (75%) and FT3I (80%), carried out on the same occasions during the early follow-up period. Pertechnetate uptake can be a useful guide to management by promptly identifying patients likely to need further radioiodine therapy and those with transient or permanent hypothyroidism. The study confirmed some previous findings that hypothyroidism was more frequent in patients with thyroid antibodies and less frequent in patients with nodular thyroids, and it also indicated that hypothyroidism was more frequent in those treated with carbimazole before and after radioiodine, and that hyperthyroidism was more likely to persist in those treated with carbimazole before or after radioiodine.
对132例甲状腺功能亢进症患者进行放射性碘治疗后8 - 13周，评估99m锝高锝酸盐摄取情况，以评价该摄取试验在预测治疗后第一年持续存在的甲状腺功能亢进症和甲状腺功能减退症早期发生方面的有用性。该评估方法简单，结果可立即获得，其敏感性、阳性预测值和总体准确率（83%）与在早期随访期间同时进行的体外试验（游离甲状腺素指数（FT4I）为75%，游离三碘甲状腺原氨酸指数（FT3I）为80%）相比更具优势。高锝酸盐摄取可以通过迅速识别可能需要进一步放射性碘治疗的患者以及患有短暂性或永久性甲状腺功能减退症的患者，为治疗管理提供有用的指导。该研究证实了一些先前的发现，即甲状腺抗体阳性患者甲状腺功能减退症更常见，结节性甲状腺患者甲状腺功能减退症较少见，并且还表明，在放射性碘治疗前后使用卡比马唑治疗的患者中甲状腺功能减退症更常见，而在放射性碘治疗前后使用卡比马唑治疗的患者中甲状腺功能亢进症更可能持续存在。
